Characterization of cross protection of Swine-Origin Influenza Virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination

Journal of Biomedical Science

Yeau-Ching Wang¹  Der-Ming Chu²  Hsieh-Ling Wu¹  Chuan-Chang Chuang¹  Hui-Tsu Lin¹ 

[1] Institute of Preventive Medicine, National Defense Medical Center, PO Box 90048–700, San-Hsia, Taiwan;Tri-Service General Hospital, National Defense Medical Center, Taipei, 100, Taiwan

关键词: MPLA;    Alum;    Adjuvant;    H5N1;    H1N1;    S-OIV;   

Others  :  824135
DOI  :  10.1186/1423-0127-20-19

 received in 2012-12-25, accepted in 2013-03-18,  发布年份 2013

【 摘 要 】

Background

Influenza virus has antigen drift and antigen shift effect, vaccination with some influenza vaccine might not induce sufficient immunity for host to the threat of other influenza virus strains. S-OIV H1N1 and H5N1 influenza vaccines in single-dose immunization were evaluated in mice for cross protection to the challenge of A/California/7/2009 H1N1 or NIBRG-14 H5N1 virus.

Results

Both H1N1 and H5N1 induced significant homologous IgG, HAI, and microneutralization antibody responses in the mice, while only vaccines plus adjuvant produced significant heterogeneous IgG and HAI antibody responses. Both alum and MPLA adjuvants significantly reduced the S-OIV H1N1 vaccine dose required to elicit protective HAI antibody titers from 0.05 μg to 0.001 μg. Vaccines alone did not protect mice from challenge with heterogeneous influenza virus, while H5N1 vaccine plus alum and MPLA adjuvants did. Mouse body weight loss was also less significant in the presence of adjuvant than in the vaccine without adjuvant. Furthermore, both H1N1 and H5N1 lung viral titers of immunized mice were significantly reduced post challenge with homologous viruses.

Conclusion

Only in the presence of MPLA adjuvant could the H5N1 vaccine significantly reduce mouse lung viral titers post H1N1 virus challenge, and not vice versa. MPLA adjuvant induced cross protection with a single dose vaccination to the challenge of heterogeneous influenza virus in mice. Lung viral titer seemed to be a better indicator compared to IgG, neutralization antibody, and HAI titer to predict survival of mice infected with influenza virus.

【 授权许可】

   
2013 Lin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]WHO: Pandemic (H1N1) 2009 - update 85. Available: http://www.who.int/csr/don/2010_01_29/en/index.html webcite. Accessed 8 February, 2010.
• [2]Hancock KV, Veguilla XL, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM: Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
• [3]Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
• [4]CDC: Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58:521-524.
• [5]Ninomiya A, Imai M, Tashiro M, Odagiri T: Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25:3554-3560.
• [6]Philippa J, Baas C, Beyer W, Bestebroer T, Fouchier R, Smith D, Schaftenaar W, Osterhaus A: Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine. Vaccine 2007, 25:3800-3808.
• [7]Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA: Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25:4283-4290.
• [8]Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD: ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999, 17:1355-1358.
• [9]Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM: Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191:1210-1215.
• [10]Wellemans V, Laurent S, Hélie P, ElAzhary Y: Immunostimulatory properties of a novel adjuvant administered with inactivated influenza virus vaccine. Vet Res 2007, 38:1-14.
• [11]Petrovsky N, Aguilar JC: Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82:488-496.
• [12]Miyaki C, Quintilio W, Miyaji EN, Botosso VF, Kubrusly FS, Santos FL, Iourtov D, Higashi HG, Raw I: Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 2010, 28:2505-2509.
• [13]Chen Z, Wang W, Zhou H Jr, Suguitan AL, Shambaugh C, Kim L, Zhao J, Kemble G, Jin H: Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84:44-51.
• [14]Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Brühl P, Kreil TR, Ehrlich HJ, Barrett PN: A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:1-7.
• [15]Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM: Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science 2009, 325:484-487.
• [16]Tamura S, Hasegawa H, Kurata T: Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis 2010, 63:8-15.
• [17]Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F: Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16:960-968.
• [18]Quintilio W, Kubrusly FS, Iourtov D, Miyaki C, Sakauchi MA, Lúcio F, Dias Sde C, Takata CS, Miyaji EN, Higashi HG, Leite LC, Raw I: Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 2009, 27:4219-4224.
• [19]Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I: AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 2010, 28:3076-3079.
• [20]Dormitzer PR, Rappuoli R, Casini D, O’Hagan D, Runham C, Montomoli E, Baudner B, 3rd Donnelly JJ, Lapini G: Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLOS Curr Influenza PRN 2009, 1025.
• [21]WHO: Serological diagnosis of influenza by microneutralization assay. In WHO Global Influenza Surveillance Network: Manual for the laboratory diagnosis and virological surveillance of influenza. [World Health Organization 20, Avenue Appia, 1211 Geneva 27, Switherland. 2.G ]: WHO Press; 2011:63-77.
• [22]Wood JM, Schild GC, Newman RW, Seagroatt V: An improved singleradial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5:237-247.
• [23]Wood JM, Mumford J, Schild GC, Webster RG, Nicholson KG: Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand 1986, 64:169-177.
• [24]Reed LJ, Muench HA: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
• [25]Nicholson KG, Tyrrell DA, Harrison P, Potter CW, Jennings R, Clark A, Schild GC, Wood JM, Yetts R, Seagroatt V, Huggins A, Anderson SG: Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 1979, 7:123-136.
• [26]Eberhardt KR, Fligner MA: A comparison of two tests for equality of two proportions. Am Stat 1997, 31:151-155.
• [27]Robbins H: A fundamental question of practical statistics. Am. Stat 1977, 31:97.
• [28]MacLeoda MKL, McKeea AS, Davida A, Wangb J, Masonb R, Kapplera JW, Marracka P: Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A. 2011, 108:7914-7919.
• [29]Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC: The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
• [30]Chen GL, Min JY, Lamirande EW, Santos C, Jin H, Kemble G, Subbarao K: Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. J Infect Dis 2011, 203:930-936.